Radionuclide therapy is an established practice within °×С½ãÂÛ̳ Hospital.
Currently we receive referrals both
nationally and internationally for the treatment of a range of
conditions including neuroendocrine tumours (NETs), thyroid carcinoma,
meningioma and pituitary tumours.
We also provide conventional
radioiodine therapy on an out-patient basis for the treatment of
thyrotoxicosis.
We are one of only two centres in the UK to offer paediactric radionuclide therapy.
Within °×С½ãÂÛ̳H, we have 10 dedicated rooms for Radionuclide
therapy.
These are state-of-the-art, en-suite and lead-lined with a separate room situated adjacent that is designated for comforters and carers.
We offer state-of-the-art diagnostic imaging assessment to monitor eligibility for radionuclide therapy, incorporating 123I-mIBG (Metaiodobenzylguanidine) scintigraphy, 18F-FDG and 68Ga-DOTATATE PETCT. Additionally, assessments can be performed on the PET/MR machine located in the °×С½ãÂÛ̳H cancer centre. This is the first machine of its kind in the UK.
Referrals for therapy are discussed in multi-disciplinary meetings comprising a range of medical, scientific and technical staff, where case histories are reviewed together with imaging studies.
A recent addition to the service is the use of 177Lu-DOTATATE therapy to treat patients with Neuroblastomas. 68Ga-DOTATATE PET/CT is used to scan children with neuroblastoma and identify those suitable for radionuclide therapy with 177Lu-DOTATATE. We have shown, for what is to our knowledge the first time, that treatment with 177Lu-DOTATATE is safe and feasible in children with relapsed or primary refractory high-risk neuroblastomas.